Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 39%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is a global science and technology company operating in the biotechnology, life sciences, and diagnostics sectors. The company has a solid track record of organic growth and strategic acquisitions, and their bioprocessing segment, which represents more than 25% of revenue, is showing strong demand trends. With a culture of continuous improvement and a focus on sustainability, Danaher is well positioned for long-term success in their key markets.

Bears say

Danaher is facing difficulties in its respiratory testing business as it has seen a decrease in demand for its molecular diagnostics products, resulting in a significant portion of its revenue being reliant on this seasonal and variable market. Additionally, its current valuation at a 15x P/E multiple, which is consistent with its large medtech competitors, reflects a lack of premium awarded to its Tools segment. Despite positive signs of growth in its biotechnology and diagnostic segments, Danaher's growth rebound may take longer to occur, resulting in a downside risk for its stock.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 39% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $237.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $237.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.